Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Faeth Therapeutics, Inc. (FTH)

Faeth Therapeutics adds Adam Schayowitz to board, expanding it to seven directors

Neutral Impact 2 of 5 leadership Written later

Faeth Therapeutics' board increased its size from six to seven directors and appointed Adam Schayowitz, Ph.D., as a Class III director effective immediately. Dr. Schayowitz currently serves as Executive Vice President and Head of Research and Development at Zymeworks Inc., and his board seat comes with a cash retainer and an option to buy 25,000 shares.

Key points

  • Board expanded from six to seven directors; appointment made October 23, 2026, effective immediately
  • Dr. Schayowitz (age 46) is EVP and Head of Research and Development at Zymeworks Inc. since April 2026
  • Initial equity award is an option on 25,000 shares under the 2026 Equity Incentive Plan, vesting monthly through the third anniversary of grant

The filing

CompanyFaeth Therapeutics, Inc. (FTH)
Form8-K, current report
Filed with the SECOct 27, 2026, 7:33 AM ET
Accession number0001193125-26-432688

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.